European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1063-1075, December 2006

Yolk sac tumours of the ovary: an update

  • P. Dällenbach

      Affiliations

    • Department of Gynaecology and Obstetrics, Division of Gynaecology, Senology and Surgical Gynaecologic Oncology Unit, Geneva University Hospitals, 30 boulevard de la Cluse, 1211 Genève 14, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 22 382 6816; fax: +41 22 382 4424.
  • ,
  • H. Bonnefoi

      Affiliations

    • Department of Medicine, Medical Gynaecologic Oncology Unit, Geneva University Hospitals, Switzerland
  • ,
  • M.-F. Pelte

      Affiliations

    • Department of Pathology, Division of Clinical Pathology, Geneva University Hospitals, Switzerland
  • ,
  • G. Vlastos

      Affiliations

    • Department of Gynaecology and Obstetrics, Division of Gynaecology, Senology and Surgical Gynaecologic Oncology Unit, Geneva University Hospitals, 30 boulevard de la Cluse, 1211 Genève 14, Switzerland

Accepted 17 July 2006.

Abstract 

Aims

Yolk sac tumours of the ovary (YST), also called endodermal sinus tumours (EST) are rare and highly malignant tumours of utmost importance occurring in children and young adults. In the past, outcome was very poor and the disease was almost always fatal. With the refinement of chemotherapeutic regimens in the last several decades, survival rates have improved dramatically and fertility preserving surgery has become possible. The aim of this review is to provide the reader with an analysis of the available literature and a rational approach to patient management.

Methods

We performed a literature search in the PubMed database and the reference lists of relevant articles concerning yolk sac tumours of the ovary.

Findings and conclusion

There are no randomised studies relating to the management of YST of the ovary. The available literature is composed of retrospective reviews and case reports that span several decades. Prognosis nowadays is good in stage I and II but still comparable to that of ovarian epithelial cancer in stage III and IV. The overall good prognosis is due to the fact that most of ovarian YST are diagnosed at an early stage where 5years survival reaches 95%. Appropriate surgical treatment for patients where fertility needs to be preserved consists in laparotomy with unilateral salpingo-oophorectomy, peritoneal cytologic studies, omentectomy, multiple peritoneal and abdominal biopsies and resection of all visible disease. Three courses of BEP (bleomycin, etoposide, cisplatin) is the current standard therapy and four courses is recommended in case of bulky residual disease after surgery. Serum alpha-feto-protein (AFP) is a useful marker for the diagnosis and management of YST.

Keywords: Yolk sac tumours, Management, Fertility preservation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0748-7983(06)00277-0

doi:10.1016/j.ejso.2006.07.010

European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1063-1075, December 2006